Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL29191362 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL17554250 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL17554249 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL45216 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL29191363 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28996640 | 0.98 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8828961 | 0.98 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8828976 | 0.98 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL17874441 | 0.93 | SLC7A5 (0.80) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21333402 | 0.93 | SLC7A5 (0.80) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026097617-A1 | RECOMBINANT HIRUDIN WITH TYROSINE SULFATION, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉元启合生科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2024062082-A1 | ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE | DOMAIN THERAPEUTICS (FR) | 2024-03-28 | — | — | WO | claimed |
| WO-2024062072-A2 | ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE | DOMAIN THERAPEUTICS (FR) | 2024-03-28 | — | — | WO | claimed |
| US-20230416341-A1 | IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS | THE UNIVERSITY OF SYDNEY (AU) | 2023-12-28 | — | — | US | claimed |
| EP-4171602-A2 | CCR8 ANTIBODIES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| WO-2023014879-A2 | SULFATED POLYPEPTIDES FOR SYSTEMIC DELIVERY | SUMMATION BIO, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| CN-115629169-A | Extract and preparation containing the same | 日本脏器制药株式会社 | 2023-01-20 | — | — | CN | claimed |
| CN-115629217-A | Extract and preparation containing the same | 日本脏器制药株式会社 | 2023-01-20 | — | — | CN | claimed |
| WO-2022103990-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PHOSFISH LLC (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PHOSFISH LLC | 2022-05-12 | — | — | US | claimed |
| WO-1998046771-A2 | HIGHLY PURIFIED MOCARHAGIN, A COBRA VENOM PROTEASE, POLYNUCLEOTIDES ENCODING SAME, RELATED PROTEASES, AND THERAPEUTIC USES THEREOF | GENETICS INSTITUTE, INC. (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | claimed |
| US-5716836-A | Anti-sulfated tyrosine antibody specific for sulfated tyrosine, process for producing the same, and hybridoma capable of producing anti-sulfated tyrosine monoclonal antibody specific for sulfated tyrosine | UNITIKA LTD. (JP) | 1998-02-10 | — | — | US | claimed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | claimed |
| US-5614554-A | RETROVIRUS, SULFATED TYROSINE | NIPPON FLOUR MILLS CO., LTD. (JP) | 1997-03-25 | — | — | US | claimed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | claimed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | claimed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | claimed |
| US-4769445-A | Process for the solid phase synthesis of peptides which contain sulfated tyrosine | PENNWALT CORPORATION (US) | 1988-09-06 | — | — | US | claimed |
| EP-0161468-A2 | Process for the solid phase synthesis of peptides which contain sulfated tyrosine | PENNWALT CORPORATION (US) | 1985-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PTMS, ACP1, SRMS | CHRM2 4677/4885ADRA2A 4840/4885CHRM1 4696/4885 |
| US-20230416341-A1 | IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS | FGB, F2, SERPINC1 | CHRM2 4794/4885ADRA2A 4675/4885CHRM1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.